Decreased gene expression of glial and neuronal glutamate transporters after chronic antipsychotic treatment in rat brain

Neuroscience Letters

Volumn 347, Issue 2, 2003, Pages 81-84

  Schmitt, Andrea ^a   Zink, Mathias ^a   Petroianu, Georg ^a   May, Brigitte ^a   Braus, Dieter F ^a   Henn, Fritz A ^a  

^a CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

Author keywords

Clozapine; Gene expression; Glutamate transporters; Haloperidol; Schizophrenia

Indexed keywords

CLOZAPINE; GLUTAMATE TRANSPORTER; HALOPERIDOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CADAVER; CINGULATE GYRUS; CONTROLLED STUDY; CORPUS STRIATUM; DOWN REGULATION; DRUG MECHANISM; EXTRAPYRAMIDAL SYMPTOM; FRONTAL CORTEX; GENE EXPRESSION; GLIA; HIPPOCAMPUS; HUMAN; IN SITU HYBRIDIZATION; LIMBIC CORTEX; LONG TERM CARE; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; NUCLEUS ACCUMBENS; PARIETAL LOBE; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

EID: 0038641323     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3940(03)00653-0     Document Type: Article

References (25)

1. 3H]D-aspartate binding to glutamate uptake sites in striatal and accumbens tissue in patients with schizophrenia. Neurosci. Lett. 232:1997;13-16.
2. Carlsson A., Hansson L.O., Waters N., Carlsson M.L. A glutamatergic deficiency model of schizophrenia. Br. J. Psychiatry Suppl. 37:1999;2-6.
3. Conti F., DeBiasi S., Minelli A., Rothstein J.D., Melone M. EAAC1, a high-affinity glutamate transporter, is localized to astrocytes and gabaergic neurons besides pyramidal cells in the rat cerebral cortex. Cereb. Cortex. 8:1998;108-116.
4. Danbolt N.C. Glutamate uptake. Prog. Neurobiol. 65:2001;1-105.
5. Deakin J.F., Slater P., Simpson M.D., Gilchrist A.C., Skan W.J., Royston M.C., Reynolds G.P., Cross A.J. Frontal cortical and left temporal glutamatergic dysfunction in schizophrenia. J. Neurochem. 52:1989;1781-1786.
6. De Souza I.E., McBean G.J., Meredith G.E. Chronic haloperidol treatment impairs glutamate transport in the rat striatum. Eur. J. Pharmacol. 382:1999;139-142.
7. Fitzgerald L.W., Deutch A.Y., Gasic G., Heinemann S.F., Nestler E.J. Regulation of cortical and subcortical glutamate receptor subunit expression by antipsychotic drugs. J. Neurosci. 15:1995;2453-2461.
8. Gadea A., Lopez-Colome A.M. Glial transporters for glutamate, glycine and GABA I. Glutamate transporters. J. Neurosci. Res. 63:2001;453-460.
9. Goldman-Rakic P.S. Prefrontal cortical dysfunction in schizophrenia: the relevance of working memory. Carroll B.J., Barrett N.A. Psychopathology and the Brain. 1991;1-21 Raven Press, New York.
10. Jentsch J.D., Roth R.H. The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology. 20:1999;201-225.
11. Kim J.S., Kornhuber H.H., Schmid-Burgk W., Holzmüller B. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia. Neurosci. Lett. 20:1980;379-382.
12. Konradi C., Heckers S. Antipsychotic drugs and neuroplasticity: insights into the treatment and neurobiology of schizophrenia. Biol. Psychiatry. 50:2001;729-742.
13. Malenka R.C., Nicoll R.A. Long-term potentiation - a decade of progress? Science. 285:1999;1870-1874.
14. McCullumsmith R.E., Meador-Woodruff J.H. Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder. Neuropsychopharmacology. 26:2002;368-375.
15. Melone M., Bragina L., Conti F. Clozapine-induced reduction of glutamate transport in the frontal cortex is not mediated by GLAST and EAAC1. Mol. Psychiatry. 8:2003;12-13.
16. Melone M., Vitellaro-Zuccarello L., Vallejo-Illarramendi A., Perez-Samartin A., Matute C., Cozzi A., Pellegrini-Giampietro D.E., Rothstein J.D., Conti F. The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine. Mol. Psychiatry. 6:2001;380-386.
17. Miller D.D. Review and management of clozapine side effects. J. Clin. Psychiatry. 61:2000;14-17.
18. Ohnuma T., Augood S.J., Arai H., McKenna P.J., Emson P.C. Expression of the human excitatory amino acid transporter 2 and metabotropic glutamate receptors 3 and 5 in the prefrontal cortex from normal individuals and patients with schizophrenia. Brain Res. Mol. Brain Res. 56:1998;207-217.
19. Olney J.W., Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch. Gen. Psychiatry. 52:1995;998-1007.
20. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 2nd Edition:1986;Academic Press, San Diego, CA.
21. Rothstein J.D., Martin L., Levey A.I., Dykes-Hoberg M., Jin L., Wu D., Nash N., Kuncl R.W. Localization of neuronal and glial glutamate transporters. Neuron. 13:1994;713-725.
22. Schmitt A., Zink M., Müller B., May B., Herb A., Jatzko A., Braus D.F., Henn F.A. Effects of long-term antipsychotic treatment on NMDA receptor binding and gene expression of subunits. Neurochem. Res. 28:2003;235-241.
23. Schneider J.S., Wade T., Lidsky T.I. Chronic neuroleptic treatment alters expression of glial glutamate transporter GLT-1 mRNA in the striatum. NeuroReport. 9:1998;133-136.
24. Simpson M.D., Slater P., Deakin J.F. Comparison of glutamate and gamma-aminobutyric acid uptake binding sites in frontal and temporal lobes in schizophrenia. Biol. Psychiatry. 44:1998;423-427.
25. Smith R.E., Haroutunian V., Davis K.L., Meador-Woodruff J.H. Expression of excitatory amino acid transporter transcripts in the thalamus of subjects with schizophrenia. Am. J. Psychiatry. 158:2001;1393-1399.